The Dana-Farber Cancer Institute and Quest Diagnostics, the laboratory testing company, are conducting a study to measure the prevalence of COVID-19 among individuals with or at risk of developing multiple myeloma. The aim of the Immune Profiling with Antibody-based COVID-19 Testing study, or IMPACT, is to understand what happens to the immune system during a COVID-19 infection in people with multiple myeloma or myeloma precursor conditions. Precursor conditions include MGUS, or monoclonal gammopathy of undetermined…
You must be logged in to read/download the full post.
The post Dana-Farber, Quest Diagnostics Studying COVID-19 Prevalence in Myeloma appeared first on BioNewsFeeds.